{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:50:19Z","timestamp":1786985419841,"version":"build-2736575974"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["AARFD-17-529742"],"award-info":[{"award-number":["AARFD-17-529742"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["NS099328"],"award-info":[{"award-number":["NS099328"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007161","name":"Boston University","doi-asserted-by":"publisher","award":["1N4R"],"award-info":[{"award-number":["1N4R"]}],"id":[{"id":"10.13039\/100007161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003924","name":"Edward Lowe Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["NS099328"],"award-info":[{"award-number":["NS099328"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["NS121826"],"award-info":[{"award-number":["NS121826"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["AG071985"],"award-info":[{"award-number":["AG071985"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007709","name":"Michigan State University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007709","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025348","name":"Lowe Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012394","name":"Robert J Kleberg Jr and Helen C Kleberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012394","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bmc.2024.117990","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:45:50Z","timestamp":1731113150000},"page":"117990","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against \u03b1-synuclein and 2N4R tau"],"prefix":"10.1016","volume":"116","author":[{"given":"Ahmed A.","family":"Elbatrawy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiwo A.","family":"Ademoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Alnakhala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Plascencia-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Perry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Dettmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117990_b0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","article-title":"The probabilistic model of Alzheimer disease: the amyloid hypothesis revised","volume":"23","author":"Frisoni","year":"2022","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bmc.2024.117990_b0010","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJM2003ra020003","article-title":"Alzheimer\u2019s disease and Parkinson\u2019s disease","volume":"348","author":"Guttmacher","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2024.117990_b0015","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer\u2019s disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2024.117990_b0020","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","article-title":"Alzheimer\u2019s disease: Strategies for disease modification","volume":"9","author":"Citron","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2024.117990_b0025","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.bmc.2024.117990_b0030","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1021\/acssensors.1c00338","article-title":"\u201cTurn-On\u201d quinoline-based fluorescent probe for selective imaging of tau aggregates in Alzheimer\u2019s disease: rational design, synthesis, and molecular docking","volume":"6","author":"Elbatrawy","year":"2021","journal-title":"ACS Sens."},{"key":"10.1016\/j.bmc.2024.117990_b0035","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1146\/annurev-neuro-072116-031153","article-title":"Propagation of Tau aggregates and neurodegeneration","volume":"40","author":"Goedert","year":"2017","journal-title":"Annu Rev Neurosci"},{"key":"10.1016\/j.bmc.2024.117990_b0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.bmc.2024.117990_b0045","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0896-6273(00)80615-7","article-title":"Tau mutations cause frontotemporal dementias","volume":"21","author":"Goedert","year":"1998","journal-title":"Neuron"},{"key":"10.1016\/j.bmc.2024.117990_b0050","first-page":"15","article-title":"Human tau isoforms and proteolysis for production of toxic tau fragments in neurodegeneration","author":"Boyarko","year":"2021","journal-title":"Front NEurosci."},{"key":"10.1016\/j.bmc.2024.117990_b0055","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.neuroscience.2022.04.024","article-title":"Tau aggregation","volume":"2023","author":"Hern\u00e1ndez","year":"2023","journal-title":"Neuroscience"},{"key":"10.1016\/j.bmc.2024.117990_b0060","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/s41594-018-0057-1","article-title":"Mapping interactions with the chaperone network reveals factors that protect against tau aggregation","volume":"25","author":"Mok","year":"2018","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.bmc.2024.117990_b0065","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1021\/acschemneuro.0c00281","article-title":"Dual targeting of monomeric tau and \u03b1-synuclein aggregation: a new multitarget therapeutic strategy for neurodegeneration","volume":"11","author":"Gabr","year":"2020","journal-title":"ACS Chem Nerosci"},{"key":"10.1016\/j.bmc.2024.117990_b0070","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1002\/pro.3499","article-title":"Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior","volume":"27","author":"Ghag","year":"2018","journal-title":"Protein Sci"},{"key":"10.1016\/j.bmc.2024.117990_b0075","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1326-6-39","article-title":"Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice","volume":"6","author":"Lasagna-Reeves","year":"2011","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.bmc.2024.117990_b0080","doi-asserted-by":"crossref","first-page":"23063","DOI":"10.1074\/jbc.M111.237974","article-title":"Characterization of prefibrillar tau oligomers in vitro and in Alzheimer disease","volume":"286","author":"Patterson","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117990_b0085","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1042\/BST20120134","article-title":"Tau oligomers and tau toxicity in neurodegenerative disease","volume":"40","author":"Ward","year":"2012","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.bmc.2024.117990_b0090","first-page":"6","article-title":"Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups","author":"Soeda","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117990_b0095","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neures.2005.11.009","article-title":"Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer\u2019s disease","volume":"54","author":"Maeda","year":"2006","journal-title":"Neurosci Res"},{"key":"10.1016\/j.bmc.2024.117990_b0100","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/anie.200802621","article-title":"Development of tau aggregation inhibitors for Alzheimer\u2019s disease","volume":"48","author":"Bulic","year":"2009","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2024.117990_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00363","article-title":"Autonomic dysfunction in \u03b1-synucleinopathies","volume":"10","author":"Mendoza-Vel\u00e1squez","year":"2019","journal-title":"Front Neurol"},{"key":"10.1016\/j.bmc.2024.117990_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.bmc.2024.117990_b0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","article-title":"100 years of Lewy pathology","volume":"9","author":"Goedert","year":"2013","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.bmc.2024.117990_b0120","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature10324","article-title":"\u03b1-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation","volume":"477","author":"Bartels","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117990_b0125","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jmb.2009.03.021","article-title":"The first N-terminal amino acids of \u03b1-synuclein are essential for \u03b1-helical structure formation in vitro and membrane binding in yeast","volume":"389","author":"Vamvaca","year":"2009","journal-title":"J Mol Biol"},{"key":"10.1016\/j.bmc.2024.117990_b0130","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1038\/ncomms4827","article-title":"Direct observation of the three regions in \u03b1-synuclein that determine its membrane-bound behaviour","volume":"5","author":"Fusco","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117990_b0135","doi-asserted-by":"crossref","first-page":"22680","DOI":"10.1074\/jbc.M101181200","article-title":"Ca2+ binding to \u03b1-synuclein regulates ligand binding and oligomerization","volume":"276","author":"Nielsen","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117990_b0140","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1021\/ja209829m","article-title":"Mechanisms of protein oligomerization: Inhibitor of functional amyloids templates \u03b1-synuclein fibrillation","volume":"134","author":"Horvath","year":"2012","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.bmc.2024.117990_b0145","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that \u03b1-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmc.2024.117990_b0150","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1021\/acschemneuro.7b00261","article-title":"Comparison of \u03b1-synuclein fibril inhibition by four different amyloid inhibitors","volume":"8","author":"Jha","year":"2017","journal-title":"ACS Chem Nerosci"},{"key":"10.1016\/j.bmc.2024.117990_b0155","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1093\/brain\/aww238","article-title":"A de novo compound targeting \u03b1-synuclein improves deficits in models of Parkinson\u2019s disease","volume":"139","author":"Wrasidlo","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.bmc.2024.117990_b0160","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jnen\/62.4.389","article-title":"Colocalization of tau and alpha-synuclein epitopes in Lewy bodies","volume":"62","author":"Ishizawa","year":"2003","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.bmc.2024.117990_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms21145030","article-title":"Tau and alpha synuclein synergistic effect in neurodegenerative diseases: when the periphery is the core","volume":"21","author":"Vacchi","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117990_b0170","doi-asserted-by":"crossref","DOI":"10.1186\/s40035-022-00293-2","article-title":"Propagation of tau and \u03b1-synuclein in the brain: therapeutic potential of the glymphatic system","volume":"11","author":"Lopes","year":"2022","journal-title":"Transl Neurodegener."},{"key":"10.1016\/j.bmc.2024.117990_b0175","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1750-1326-9-43","article-title":"Alpha-synuclein and tau: teammates in neurodegeneration?","volume":"9","author":"Moussaud","year":"2014","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.bmc.2024.117990_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026609","article-title":"Tau enhances \u03b1-synuclein aggregation and toxicity in cellular models of synucleinopathy","volume":"6","author":"Badiola","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bmc.2024.117990_b0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117613","article-title":"Discovery of small molecule benzothiazole and indole derivatives tackling tau 2N4R and \u03b1-synuclein fibrils","volume":"100","author":"Elbatrawy","year":"2024","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117990_b0190","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1021\/cn200002t","article-title":"Rhodanine and thiohydantoin derivatives for detecting tau pathology in Alzheimer\u2019s brains","volume":"2","author":"Ono","year":"2011","journal-title":"ACS Chem Nerosci"},{"key":"10.1016\/j.bmc.2024.117990_b0195","doi-asserted-by":"crossref","first-page":"9215","DOI":"10.1002\/anie.200704051","article-title":"Rhodanine-based tau aggregation inhibitors in cell models of tauopathy","volume":"46","author":"Bulic","year":"2007","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2024.117990_b0200","doi-asserted-by":"crossref","first-page":"20102","DOI":"10.1021\/acsomega.3c02668","article-title":"5-Nitro-1,2-benzothiazol-3-amine and N-ethyl-1-[(ethylcarbamoyl)(5-nitro-1,2-benzothiazol-3-yl)amino]formamide modulate \u03b1-synuclein and tau aggregation","volume":"8","author":"Ramirez","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2024.117990_b0205","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.drudis.2022.01.009","article-title":"Tau protein aggregation: Key features to improve drug discovery screening","volume":"27","author":"Giovannini","year":"2022","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.bmc.2024.117990_b0210","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/brain\/awv376","article-title":"Brain propagation of transduced \u03b1-synuclein involves non-fibrillar protein species and is enhanced in \u03b1-synuclein null mice","volume":"139","author":"Helwig","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.bmc.2024.117990_b0215","article-title":"Functional selection of tau oligomerization-inhibiting aptamers","volume":"63","author":"Wang","year":"2024","journal-title":"Angew Chem Int Ed"},{"key":"10.1016\/j.bmc.2024.117990_b0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/life11010028","article-title":"Tau oligomers neurotoxicity","volume":"11","author":"Niewiadomska","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.bmc.2024.117990_b0225","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1471-4159.2009.06511.x","article-title":"Tau oligomers and aggregation in Alzheimer\u2019s disease","volume":"112","author":"Meraz-R\u00edos","year":"2010","journal-title":"J Neurochem"},{"key":"10.1016\/j.bmc.2024.117990_b0230","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0076-6879(06)13012-8","article-title":"Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins","volume":"413","author":"Bitan","year":"2006","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.bmc.2024.117990_b0235","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/092986606775974384","article-title":"The early events of \u03b1-synuclein oligomerization revealed by photo- induced cross-linking","volume":"13","author":"Li","year":"2006","journal-title":"Protein Pept Lett"},{"key":"10.1016\/j.bmc.2024.117990_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133574","article-title":"Anti-fibrillization effects of sulfonamide derivatives on \u03b1-synuclein and hyperphosphorylated tau isoform 1N4R","volume":"1267","author":"Fortin","year":"2022","journal-title":"J Mol Struct"},{"key":"10.1016\/j.bmc.2024.117990_b0245","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.3390\/ijms21155193","article-title":"rapid alpha-synuclein toxicity in a neural cell model and its rescue by a stearoyl-CoA desaturase inhibitor","volume":"21","author":"Terry-Kantor","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2024.117990_b0250","doi-asserted-by":"crossref","first-page":"20760","DOI":"10.1073\/pnas.1903216116","article-title":"Cell models of lipid-rich \u03b1-synuclein aggregation validate known modifiers of \u03b1-synuclein biology and identify stearoyl-CoA desaturase","volume":"116","author":"Imberdis","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmc.2024.117990_b0255","doi-asserted-by":"crossref","first-page":"16036","DOI":"10.1038\/s41598-021-95396-7","article-title":"Equine pituitary pars intermedia dysfunction: a spontaneous model of synucleinopathy","volume":"11","author":"Fortin","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2024.117990_b0260","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1074\/mcp.O114.044412","article-title":"Protein interaction module\u2013assisted function X (PIMAX) approach to producing challenging proteins including hyperphosphorylated tau and active CDK5\/p25 kinase complex","volume":"14","author":"Sui","year":"2015","journal-title":"Mol. Cell. Proteom."},{"key":"10.1016\/j.bmc.2024.117990_b0265","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1007\/s12035-020-02034-w","article-title":"Hyperphosphorylation renders tau prone to aggregate and to cause cell death","volume":"57","author":"Liu","year":"2020","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.bmc.2024.117990_b0270","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf6707","article-title":"Biogenic metallic elements in the human brain?","volume":"7","author":"Everett","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.bmc.2024.117990_b0275","doi-asserted-by":"crossref","first-page":"24873","DOI":"10.1038\/srep24873","article-title":"High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer\u2019s disease","volume":"6","author":"Plascencia-Villa","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2024.117990_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2023.100938","article-title":"Discovery of 4-aminoindole carboxamide derivatives to curtail alpha-synuclein and tau isoform 2N4R oligomer formation","volume":"5","author":"Ramirez","year":"2023","journal-title":"Results Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624004048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089624004048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T20:50:32Z","timestamp":1778791832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089624004048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":56,"alternative-id":["S0968089624004048"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117990","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the rhodanine universe: Design and synthesis of fluorescent rhodanine-based derivatives as anti-fibrillar and anti-oligomer agents against \u03b1-synuclein and 2N4R tau","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117990","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"117990"}}